{
    "nct_id": "NCT06840483",
    "official_title": "Phase 2 Study of Zelenectide Pevedotin in Participants With NECTIN4 Amplified Advanced Breast Cancer",
    "inclusion_criteria": "Histologically or cytologically confirmed HR+/HER2-negative endocrine resistant/refractory breast cancer according to ASCO-CAP guidelines and received up to 3 prior lines of non-endocrine therapy for advanced disease.\n* Cohort B Specific Inclusion Criteria: Histologically or cytologically confirmed TNBC, including ER-low positive breast cancers (1-10% of cells expressing hormonal receptors by IHC), according to ASCO-CAP guidelines and have received at least 1 but no more than 3 prior lines of systemic therapy for advanced disease.\n\nExclusion Criteria\n\n* Prior treatment with any antibody drug conjugate containing an Monomethyl Auristatin E (MMAE) (vedotin) payload or other MMAE-based therapy.\n* Known hypersensitivity or allergy to any of the ingredients of any of the study interventions or MMAE.\n* Previously tested HER2-positive (IHC 3+ or ISH+) on prior pathology testing (per ASCO-CAP guidelines).\n* Active keratitis or corneal ulcerations.\n* Active or untreated CNS metastases.\n* Uncontrolled diabetes or hypertension.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent draining procedures (monthly or more frequently).\n* Active interstitial lung disease or penumonitis requiring ongoing treatment with steriods (>10mg/day of prednisone or equivalent) or other immunosupressive medications.\n* Requirement, while on study, for treatment with strong inhiitors or strong inducers of human cytochrome P450 3A (CYP3A) or inhibitors of P-glycoprotein (P-gp) including herbal- or food-based inhibitors.\n* Prior treatment with any systemic anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to first dose of study treatment\n\nNote: Additional protocol defined Inclusion/Exclusion criteria apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": "Inclusion Criteria\n\n* Archival or fresh tumor tissue comprised of recurrent unresectable or metastatic TNBC or HR+/HER2-negative breast cancer available for NECTIN4 gene amplification testing.\n* Confirmed NECTIN4 gene amplification by an analytically validated clinical trial assay.\n* Measurable disease as defined by RECIST v1.1.\n* Life expectancy ≥ 12 weeks.\n* Eastern Cooperative Oncology Group Performance Status of ≤ 2.\n* Cohort A Specific"
}